Mylanís ANDA for Clopidogrel Tablets Gets FDA Approval

by Kathy Jones on  May 18, 2012 at 9:59 PM Corporate News
RSS Email Print This Page Comment
Font : A-A+

Mylan Pharmaceuticals has revealed that the US Food and Drug Administration has approved its abbreviated new drug application for Clopidogrel tablets in 75mg and 300mg strengths.
 Mylanís ANDA for Clopidogrel Tablets Gets FDA Approval
Mylanís ANDA for Clopidogrel Tablets Gets FDA Approval

Clopidogrel tablets are currently marketed in the United States by Bristol-Myers Squibb and Sanofi-Aventis under the brand name Plavix and are used in treating patients with a history of myocardial infarction, stroke or established peripheral arterial disease.

Mylan Pharmaceuticals said that it will be distributing the 75mg strength of the tablets in a bottle form while the 300mg strengths will be exclusively distributed by Mylan Institutional in unit dose packs of 30 tablets.


Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Anticoagulants Modified Atkins Diet: All You Need to Know 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive